Latigo Biotherapeutics, Inc.
No SEC Form 4 filings for $LTGO in the last 30 days.
Latigo Biotherapeutics (Nasdaq: LTGO) priced its IPO at $18 per share, raising $345.6 million, according to the IPO announcement. The company said the proceeds will fund its non-opioid painkiller program. Goldman Sachs, Jefferies, Leerink and Guggenheim served as bookrunners.
Latigo Biotherapeutics Inc. (NASDAQ:LTGO) shares rose 17% after an upsized IPO. The company raised $345.6 million by selling 19.2 million shares at $18, the top of its $16 to $18 range. It priced above the marketed size, opened at $21, and has a 30-day option for 2.88 million more shares.
Latigo Biotherapeutics priced its IPO at $18.00 per share, selling 19.2 million shares for expected gross proceeds of $345.6 million, per the company’s Aug. 6, 2026 press release. Underwriters can buy 2.88 million additional shares. Shares are set to trade on Nasdaq Aug. 7, 2026 under LTGO, with SEC registration effective Aug. 6.
Over the past 7 days, alphai's AI scored 4 news stories mentioning LTGO (Latigo Biotherapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
The IPO pricing is a fresh financing event that can reduce near-term funding risk and support clinical/commercial execution.
The IPO pricing and size are a fresh, company-specific catalyst that can drive near-term liquidity, sentiment, and post-IPO trading dynamics.
The IPO pricing and imminent Nasdaq listing create a near-term tradable catalyst for LTGO, driven by supply/demand and first-day liquidity.
IPO filing and stated Phase 3 timeline can shift near-term sentiment and liquidity expectations for LTGO, but it is not yet a priced print.
alphai scores every news story that mentions LTGO with an AI model for sentiment and relevance, and aggregates insider trades from Latigo Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Latigo Biotherapeutics (Nasdaq: LTGO) priced its IPO at $18 per share, raising $345.6 million, according to the IPO announcement. The company said the proceeds will fund its non-opioid painkiller program. Goldman Sachs, Jefferies, Leerink and Guggenheim served as bookrunners.
2 min readLatigo Biotherapeutics Inc. (NASDAQ:LTGO) shares rose 17% after an upsized IPO. The company raised $345.6 million by selling 19.2 million shares at $18, the top of its $16 to $18 range. It priced above the marketed size, opened at $21, and has a 30-day option for 2.88 million more shares.
4 min readLatigo Biotherapeutics priced its IPO at $18.00 per share, selling 19.2 million shares for expected gross proceeds of $345.6 million, per the company’s Aug. 6, 2026 press release. Underwriters can buy 2.88 million additional shares. Shares are set to trade on Nasdaq Aug. 7, 2026 under LTGO, with SEC registration effective Aug. 6.
2 min readLatigo Biotherapeutics Inc. filed for an IPO to raise up to $288m, offering 16m shares at $16 to $18 each, implying about $1.1b market value at the top of the range, according to an SEC filing. The company says its lead non-opioid pain drug showed about 50% greater pain relief than Vicodin. It reported a $23m net loss for the three months ended March 31 and had $54.8m cash at June end. Shares are expected to trade on Nasdaq as LTGO.
3 min read
